“Dials Could Turn” In Genzyme Deal, But Isis First Quarter is Better
This article was originally published in The Pink Sheet Daily
Executive Summary
Isis waits for $175 million license fee, as firms iron out mipomersen details.
You may also be interested in...
Genzyme/Isis’ Mipomersen Development Outlook Pricier And Riskier After FDA Weighs In
Cardiotoxicity and outcomes requirements push back NDA timeline for the novel LDL-lowering drug.
Isis: Pondering Platform Power
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?
Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction
Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.